|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The chimera also acquired an ability to bind the FGFR1c isoform - the principal receptor that mediates the metabolic actions of FGF21 - and consequently was dramatically more effective than FGF21<sup>WT</sup> in correcting hyperglycemia and in ameliorating insulin resistance in db/db mice.
|
31631034 |
2019 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In comparison with the Con group, MR led to elevated plasma FGF21 levels and prevented the onset of hyperglycemia in NZO mice.
|
30841758 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that FGF21 reduced hyperglycemia and ameliorated insulin resistance in type 2 diabetic mice, an effect that was totally lost in type 1 diabetic mice.
|
31511499 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the effects of IOE to ameliorate hyperglycemia and adiposity may be mediated through FGF21 activating insulin signaling and increasing the expression of GLUT4 and pro-thermogenic factors.
|
31323977 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor-21 (FGF-21), an endocrine hormone, is regarded as a therapeutic target for diabetes base on its potent effects on improving hyperglycemia.
|
30551357 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long-term high fat diet-fed obese mice exhibit compromised effects of exogenous FGF21 on alleviation of hyperglycemia, hyperinsulinemia, and hyperlipidemia, accompanied with markedly reduced expression of FGF receptor-1 (FGFR1) and β-Klotho (KLB) in adipose tissues.
|
30840894 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
FGF21 has been shown to improve insulin sensitivity, reduce hyperglycemia, increase adipose tissue glucose uptake and lipolysis, and decrease body fat and weight loss by enhancing energy expenditure.
|
29869772 |
2018 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased FGF21 levels and elevated energy expenditure do not protect against hyperglycaemia and type 2 diabetes per se.
|
29550873 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we use db/db mice as a Type 2 diabetes model to determine whether FGF-21 alleviates inflammatory state while improves hyperglycemia.
|
29414665 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, we discovered for the first time that FGF21 ameliorates hyperglycemia in part via reducing renal glucose reabsorption through PPARδ mediated SGLT2 pathway.
|
30227329 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In these mice, protective pathways were uncovered for managing hyperglycemia and include augmentation of fibroblast growth factor 21 and glucagon-like peptide 1.
|
27999107 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intracerebroventricular (ICV) injection of FGF21 markedly suppressed food intake in fed mice with elevated blood glucose.
|
28374855 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to examine the combined and independent effects of hyperglycemia and hyperinsulinemia on total and bioactive FGF21 in the postprandial period in humans, and determine whether this effect is attenuated in conditions of altered insulin secretion and action.
|
28938434 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice.
|
24804243 |
2014 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A large amount of data, predominantly obtained from murine models but also from non-human primates, suggest that FGF21 ameliorates obesity-associated hyperglycemia and hyperlipidemia primarily via effects on adipose tissue and the pancreas.
|
19277467 |
2009 |